Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valtrate is a naturally occurring iridoid valepotriate compound primarily isolated from plants in the genus *Valeriana*, such as *Valeriana jatamansi* and *Valeriana officinalis*. It is being investigated as a novel therapeutic agent for its potent anti-cancer activities, particularly in pancreatic cancer and glioblastoma. Valtrate's mechanism of action involves the inhibition of the Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway, which is frequently overactivated in various malignancies and contributes to cell survival and proliferation. Additionally, valtrate has been shown to suppress the PDGFRA/MEK/ERK signaling cascade, leading to anti-proliferative and pro-apoptotic effects in cancer cells while exhibiting low toxicity toward normal cells. Although it is a constituent of valerian extracts used in traditional medicine and dietary supplements, in its purified form, it is studied as a targeted small molecule inhibitor in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valtrate.